Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

1639524692803
December 23rd, 2022

2023 Top Six Pick - Aroa Biosurgery: A Defensive Growth Stock for Investors

Wound healing products company Aroa Biosurgery (ARX: $1.10) is proving to be a very predictable performer, meeting or exceeding its sales forecasts.

For the first half of its 2023 financial year (ending 30 September) the company achieved a 44% growth in sales to NZ$29 million. The company is forecasting to be EBITDA neutral by the end of March next year.

adalta2
December 19th, 2022

Adalta Returns to IV Formulation for AD-214

Last year novel antibody company Adalta (1AD: $0.044) announced that it would be moving to develop an inhaled formulation of its lead drug candidate, AD-214. This followed preclinical studies that showed high accumulation of the compound in the liver, although no liver toxicity was observed in patients in the Phase I study.

1623118494675DR_NINA_WEBSTER
December 19th, 2022

Dimerix Completes Recruitment of First Stage in Phase III Study

Dimerix (DXB: $0.17) has completed recruitment of the first part of its Phase III study in the kidney disease FSGS (focal segmental glomerulosclerosis) with 72 patients. It will now move into the second part where an additional 72 patients will be treated for 35 weeks with placebo or active drug.

cogstate
December 19th, 2022

Lecanemab Data Presented; Positive News for Cogstate

The Phase III trial data on the emerging Alzheimer's disease drug lecanemab has been published in the New England Journal of Medicine and was presented at the recent Alzheimer's disease conference, CTAD, held in San Francisco, by Dr Sharen Cohen. Dr Cohen was an investigator on the Phase III Eisai/Biogen Alzheimer's disease study and co-authored the paper that was published.

The data is of interest to Cogstate (CGS: $1.80) and investors as Cogstate's core business is in conducting Alzheimer's disease studies, and its blue sky is the use of its cognitive diagnostic tool, licensed by Eisai, to help identify patients should an effective drug treatment for Alzheimer's disease become available.

December 18th, 2022

Anteris Technologies to Progress Heart Valve to Early Feasibility Study

Anteris Technologies (AVR: $23.20) is developing an aortic heart valve, called DurAVR THV. The device is implanted via a catheter rather than through open chest surgery and has delivered some impressive results compared to other valves implanted through the same process or through surgery.

Last month the company announced that it had reached agreement with the FDA on an early feasibility study to follow on from its first feasibility study in 13 patients. The early feasibility study will recruit 15 patients who will be implanted across seven implant centres in the US. It is only expected to take a few weeks to fully recruit.

CopyofPABWEBSITEIMAGE2
November 24th, 2022

Patrys AGM Highlights

Novel antibody company Patrys (PAB: $0.021) held its AGM this week. The presentation by its CEO James Campbell is worth reading closely.

Imricor_Logo_2020_Vendor
November 4th, 2022

Imricor Medical Systems to Focus on Dedicated MRI Labs

Imricor Medical Systems (IMR: $0.275) achieved consumable revenue of just US$115,000 for the quarter, down 15% on the previous corresponding period. However, it has increased the number of active sites by three to nine sites.

20210209pharmaxis
November 4th, 2022

Pharmaxis Releases Initial Data in Myelofibrosis

Pharmaxis (PXS: $0.066) has two drug candidates in clinical development, both based on its lysyl oxidase inhibition platform that seeks to reduce or stop collagen crosslinking that is crucial to the fibrosis process. The drug candidates are PXS-5505, being trialled in a Phase II study in myelofibrosis, and a second investigator-led study in liver cancer due to commence this year; as well as PXS-6302, which is being investigated as a treatment for existing and new scars. The trial in existing scars has reached the 75% recruitment mark.

222222
November 4th, 2022

Aroa Biosurgery - Revenue Up 44%

Aroa Biosurgery (ARX: $0.86) continues to outperform. Revenue for its first half (ending 30 September) was up 44% on the PCP to NZ$29 million. Surprisingly it has also delivered a positive EBITDA for the half year, ahead of expectations. Aroa is forecasting to be EBITDA neutral for the full year.

artworks0002238637397a3jy5t500x500
November 4th, 2022

Cogstate Signs US$17.9 Million of Contracts in September Quarter

Cogstate (CGS: $1.77) has achieved another very strong quarter of sales contracts totalling US$17.9 million after US$1.1 million in contract cancellations. Its net cashflow was just US$0.2 million.

Pages